New Models for Epileptogenesis

Epilepsy often develops after the brain is damaged, and patients commonly must take anticonvulsant drugs for a lifetime despite unpleasant side effects.

Written byLaura Spinney
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

© 2004, AAAS

In a normal neuron (top), action potentials progress down the axon and there is a less robust dendritic echo. In a person with sprouted axons (middle), action potentials are rerouted back to neighboring dendrites. But action potential reverberation can occur without sprouting (bottom). Blocked A-type K+ channels reduce inhibitory A currents allowing larger echoes. (From: K. Staley, Science, 305:482–3, July 23, 2004.)

Epilepsy often develops after the brain is damaged, and patients commonly must take anticonvulsant drugs for a lifetime despite unpleasant side effects. Such drugs target the seizures but not the underlying cause. Now, new theories promise to untangle the mechanisms of epileptogenesis and presage the possibility of a new generation of drugs that treat the initial brain damage and prevent epilepsy from developing.

In roughly half of all patients with epilepsy, the condition develops later in life after the patient sustains a brain injury such ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies